Previous 10 | Next 10 |
home / stock / ivevf / ivevf articles
Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), ...
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company foc...
The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel...
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned r...
Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), ...
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 millio...
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company f...
News, Short Squeeze, Breakout and More Instantly...
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrho...
Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term. Cash runway extended...
Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3. Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a pat...